Results of a phase I trial of the novel angiogenesis inhibitor, tecogalan sodium (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Results of a phase I trial of the novel angiogenesis inhibitor, tecogalan sodium (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 36:A628 1995. Unique Identifier : AIDSLINE ICDB/95608407
Eckhardt SG; Eckardt JR; Weiss G; Rinaldi D; Rodriguez G; Fields S; Kuhn J; Smetzer L; Higashi L; Von Hoff DD; et al; Cancer Therapy and Res. Center, San Antonio, TX 78229

Abstract: Tecogalan sodium is a novel angiogenesis inhibitor isolated from a low mol wt fraction of a sulfated polysaccharide produced by the bacterium Arthrobacter. The antitumor effect of tecogalan sodium is thought to be mediated by the inhibition of the binding of fibroblast growth factor to cellular receptors. We have conducted a phase I trial with tecogalan sodium given every 21 days to patients with solid tumors or AIDS-related Kaposi's sarcoma. A total of 104 courses have been administered to 32 patients, and 4 patients remain on study. The primary dose-limiting toxicity has been prolongation of the activated partial thromboplastin time (APTT) with peak times being 1.0-5.5 times the upper limit of normal. The APTT peaks at the end of infusion and normalizes within 5 hr. The effect of tecogalan sodium on the APTT is thought to be due to a catalytic effect on heparin cofactor II, similar to dermatan sulfate. This toxicity has been ameliorated by prolonging the infusion time. Other observed toxicities include fever and chills which respond to meperidine and acetaminophen. Pharmacokinetic studies reveal that the peak plasma concentration correlates with the peak APTT, and that little of the drug is excreted in the urine.
Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS Antineoplastic Agents/THERAPEUTIC USE Human Neovascularization, Pathologic/*PREVENTION & CONTROL Partial Thromboplastin Time Sarcoma, Kaposi's/BLOOD SUPPLY/*DRUG THERAPY/ETIOLOGY ABSTRACTKWDacquiredimmunodeficiencysyndrome/complicationsantineoplasticagents/therapeuticusehumanneovascularization,pathologic/KWDprevention&controlpartialthromboplastintimesarcoma,kaposi's/bloodsupply/KWDdrugtherapy/etiologyabstract
950830
M9580995

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .